Literature DB >> 874093

Metabolism of autologous and homologous IgG in rheumatoid arthritis.

M A Catalano, E H Krick, D H De Heer, R M Nakamura, A N Theofilopoulos, J H Vaughan.   

Abstract

The metabolism of radioiodinated IgG was studied in 20 patients with rheumatoid arthritis and 11 normal controls using autologous IgG and homologous IgG pooled from normal donors. Fractional catabolic rates in the controls were 4.44% of the autologous- and 4.29% of the homologous-labeled protein per day. The corresponding rates in the rheumatoid patients were 9.67% of the autologous- and 8.64% of the homologous-labeled protein per day. Extravascular catabolism occurred only in the rheumatoid group and accounted essentially for the entire increased catabolism of IgG observed in these patients. 10 patients were especially hypercatabolic, with fractional catabolic rates for autologous IgG greater than 10%. Moreover, they catabolized their autologous IgG significantly faster than the homologous IgG (12.6 vs. 9.9%). The increment of catabolism of autologous over homologous IgG also occurred in the extravascular compartment. These highly hypercatabolic patients had a significantly increased number of manifestations of extra-articular disease. The hypercatabolism of IgG could not be correlated with age, weight, sex, duration of disease, joint erosions, corticosteroid therapy, erythrocyte sedimentation rate, rheumatoid factor titer, serum IgG concentration, or circulating immune complexes as measured by the Raji cell radioimmunoassay. Conceivable sites of extravascular catabolism and possible causes of faster catabolism of autologous (rheumatoid) than of homologous (normal) IgG are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874093      PMCID: PMC372371          DOI: 10.1172/JCI108779

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  HEMOLYTIC COMPLEMENT IN SYNOVIAL FLUID.

Authors:  T J PEKIN; N J ZVAIFLER
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

2.  ISOTOPE STUDIES OF GAMMAGLOBULIN CATABOLISM IN COLLAGEN DISORDERS.

Authors:  B OLHAGEN; G BIRKE; L O PLANTIN; S AHLINDER
Journal:  Acta Rheumatol Scand       Date:  1963

3.  THE METABOLISM OF GAMMA GLOBULINS IN MYELOMA AND ALLIED CONDITIONS.

Authors:  C A ALPER; T FREEMAN; J WALDENSTROEM
Journal:  J Clin Invest       Date:  1963-12       Impact factor: 14.808

Review 4.  THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN.

Authors:  G E CARTWRIGHT; J W ATHENS; M M WINTROBE
Journal:  Blood       Date:  1964-12       Impact factor: 22.113

5.  STUDIES ON THE PATHOGENESIS OF RHEUMATOID JOINT INFLAMMATION. 3. THE EXPERIMENTAL PRODUCTION OF ARTHRITIS BY THE INTRA-ARTICULAR INJECTION OF PURIFIED 7S GAMMA GLOBULIN.

Authors:  R A RESTIFO; A J LUSSIER; A J RAWSON; J H ROCKEY; J L HOLLANDER
Journal:  Ann Intern Med       Date:  1965-02       Impact factor: 25.391

6.  Clinical and experimental metabolism of normal 6.6s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma.

Authors:  A SOLOMON; T A WALDMANN; J L FAHEY
Journal:  J Lab Clin Med       Date:  1963-07

7.  High specific activity iodination of gamma-globulin with iodine-131 monochloride.

Authors:  R W HELMKAMP; R L GOODLAND; W F BALE; I L SPAR; L E MUTSCHLER
Journal:  Cancer Res       Date:  1960-11       Impact factor: 12.701

8.  Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood.

Authors:  D M DONOHUE; R H REIFF; M L HANSON; Y BETSON; C A FINCH
Journal:  J Clin Invest       Date:  1958-11       Impact factor: 14.808

9.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

10.  The plasma disappearance time and catabolic half-life of I-131-labeled normal human gamma globulin in amyloidosis and inrheumatoid arthritis.

Authors:  J A MILLS; E CALKINS; A S COHEN
Journal:  J Clin Invest       Date:  1961-10       Impact factor: 14.808

View more
  8 in total

1.  Heterogeneity of the Ro/SSA antigen. Different molecular forms in lymphocytes and red blood cells.

Authors:  M D Rader; C O'Brien; Y S Liu; J B Harley; M Reichlin
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 2.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

3.  Molecular properties of the Ro/SSA antigen and enzyme-linked immunosorbent assay for quantitation of antibody.

Authors:  H Yamagata; J B Harley; M Reichlin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

4.  High-dose immunoglobulin in Felty's syndrome.

Authors:  M Ahern; J Harkness; P Maddison; S Forskitt
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

5.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15

6.  Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap.

Authors:  T Mimori; M Akizuki; H Yamagata; S Inada; S Yoshida; M Homma
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

7.  Metabolism of factor B of serum complement in rheumatoid arthritis.

Authors:  E H Krick; D H De Heer; R A Kaplan; C M Arroyave; J H Vaughan
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

8.  In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart.

Authors:  Francis Man; Alexander Koers; Panagiotis Karagiannis; Debra H Josephs; Heather J Bax; Amy E Gilbert; Tihomir S Dodev; Silvia Mele; Giulia Chiarruttini; Silvia Crescioli; Jitesh Chauhan; Julia E Blower; Margaret S Cooper; James Spicer; Sophia N Karagiannis; Philip J Blower
Journal:  Oncoimmunology       Date:  2021-09-06       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.